Efficacy and Safety of a Tri-Valent Ready-to-Use Porcine Circovirus Type 2a, <i>Mycoplasma hyopneumoniae</i> and <i>Lawsonia intracellularis</i> Vaccine in Weaned Pigs
<b>Background/Objectives</b>: This study describes multiple trials demonstrating the safety and efficacy of a tri-valent vaccine against diseases caused by Porcine Circovirus Types 2a and 2d (PCV2a, PCV2d), <i>Mycoplasma hyopneumoniae</i>, and <i>Lawsonia intracellulari...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-06-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/13/7/681 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849713681405837312 |
|---|---|
| author | Michelle Allen Frank Roerink Abigail Crowley Susan Knetter Chandra Morgan Huiling Wei Ruud Segers |
| author_facet | Michelle Allen Frank Roerink Abigail Crowley Susan Knetter Chandra Morgan Huiling Wei Ruud Segers |
| author_sort | Michelle Allen |
| collection | DOAJ |
| description | <b>Background/Objectives</b>: This study describes multiple trials demonstrating the safety and efficacy of a tri-valent vaccine against diseases caused by Porcine Circovirus Types 2a and 2d (PCV2a, PCV2d), <i>Mycoplasma hyopneumoniae</i>, and <i>Lawsonia intracellularis</i>. <b>Methods</b>: For each of the PCV2a and PCV2d onset of immunity (OOIs) and duration of immunity (DOI) studies, 25 pigs were vaccinated with a tri-valent vaccine and 25 with placebo. After dual challenge with PCV2a and porcine reproductive and respiratory virus (PRRSV) (OOI) or single challenge with PCV2d (OOI and DOI), respectively, viremia and lymphoid depletion data were collected. For each of the <i>M. hyopneumoniae</i> OOI and DOI studies, 35 to 70 pigs were vaccinated with the tri-valent vaccine and 35 to 70 with placebo. After <i>M. hyopneumoniae</i> challenge, the lungs were scored for disease. For the <i>L. intracellularis</i> OOI study, 40 to 50 pigs were vaccinated with the tri-valent and 40 to 50 with placebo. After <i>L. intracellularis</i> challenge, the intestines were scored for disease. All pigs were vaccinated at approximately 3 weeks of age, and all placebo vaccines were product matched. <b>Results</b>: Vaccinating pigs with a tri-valent vaccine reduced viremia and lymphoid depletion due to PCV2a and PCV2d, reduced lung lesions due to <i>M. hyopneumoniae</i> and reduced ileum and colonization scores due to <i>L. intracellularis</i>. <b>Conclusions</b>: The trials reported here demonstrated the safety and efficacy of the first ready-to-use PCV2, <i>M. hyopneumoniae</i>, and <i>L. intracellularis</i> vaccine for pigs. |
| format | Article |
| id | doaj-art-4eb96a5185104ff486d7f813dc5e6c8c |
| institution | DOAJ |
| issn | 2076-393X |
| language | English |
| publishDate | 2025-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj-art-4eb96a5185104ff486d7f813dc5e6c8c2025-08-20T03:13:54ZengMDPI AGVaccines2076-393X2025-06-0113768110.3390/vaccines13070681Efficacy and Safety of a Tri-Valent Ready-to-Use Porcine Circovirus Type 2a, <i>Mycoplasma hyopneumoniae</i> and <i>Lawsonia intracellularis</i> Vaccine in Weaned PigsMichelle Allen0Frank Roerink1Abigail Crowley2Susan Knetter3Chandra Morgan4Huiling Wei5Ruud Segers6Intervet Inc. (d/b/a Merck Animal Health), De Soto, KS 66018, USAIntervet Inc. (d/b/a Merck Animal Health), De Soto, KS 66018, USAIntervet Inc. (d/b/a Merck Animal Health), De Soto, KS 66018, USAIntervet Inc. (d/b/a Merck Animal Health), De Soto, KS 66018, USAIntervet Inc. (d/b/a Merck Animal Health), De Soto, KS 66018, USAIntervet Inc. (d/b/a Merck Animal Health), De Soto, KS 66018, USAIntervet International B.V., 5831 AN Boxmeer, The Netherlands<b>Background/Objectives</b>: This study describes multiple trials demonstrating the safety and efficacy of a tri-valent vaccine against diseases caused by Porcine Circovirus Types 2a and 2d (PCV2a, PCV2d), <i>Mycoplasma hyopneumoniae</i>, and <i>Lawsonia intracellularis</i>. <b>Methods</b>: For each of the PCV2a and PCV2d onset of immunity (OOIs) and duration of immunity (DOI) studies, 25 pigs were vaccinated with a tri-valent vaccine and 25 with placebo. After dual challenge with PCV2a and porcine reproductive and respiratory virus (PRRSV) (OOI) or single challenge with PCV2d (OOI and DOI), respectively, viremia and lymphoid depletion data were collected. For each of the <i>M. hyopneumoniae</i> OOI and DOI studies, 35 to 70 pigs were vaccinated with the tri-valent vaccine and 35 to 70 with placebo. After <i>M. hyopneumoniae</i> challenge, the lungs were scored for disease. For the <i>L. intracellularis</i> OOI study, 40 to 50 pigs were vaccinated with the tri-valent and 40 to 50 with placebo. After <i>L. intracellularis</i> challenge, the intestines were scored for disease. All pigs were vaccinated at approximately 3 weeks of age, and all placebo vaccines were product matched. <b>Results</b>: Vaccinating pigs with a tri-valent vaccine reduced viremia and lymphoid depletion due to PCV2a and PCV2d, reduced lung lesions due to <i>M. hyopneumoniae</i> and reduced ileum and colonization scores due to <i>L. intracellularis</i>. <b>Conclusions</b>: The trials reported here demonstrated the safety and efficacy of the first ready-to-use PCV2, <i>M. hyopneumoniae</i>, and <i>L. intracellularis</i> vaccine for pigs.https://www.mdpi.com/2076-393X/13/7/681<i>Mycoplasma hyopneumoniae</i><i>Lawsonia intracellularis</i>porcine circoviruscombination vaccine |
| spellingShingle | Michelle Allen Frank Roerink Abigail Crowley Susan Knetter Chandra Morgan Huiling Wei Ruud Segers Efficacy and Safety of a Tri-Valent Ready-to-Use Porcine Circovirus Type 2a, <i>Mycoplasma hyopneumoniae</i> and <i>Lawsonia intracellularis</i> Vaccine in Weaned Pigs Vaccines <i>Mycoplasma hyopneumoniae</i> <i>Lawsonia intracellularis</i> porcine circovirus combination vaccine |
| title | Efficacy and Safety of a Tri-Valent Ready-to-Use Porcine Circovirus Type 2a, <i>Mycoplasma hyopneumoniae</i> and <i>Lawsonia intracellularis</i> Vaccine in Weaned Pigs |
| title_full | Efficacy and Safety of a Tri-Valent Ready-to-Use Porcine Circovirus Type 2a, <i>Mycoplasma hyopneumoniae</i> and <i>Lawsonia intracellularis</i> Vaccine in Weaned Pigs |
| title_fullStr | Efficacy and Safety of a Tri-Valent Ready-to-Use Porcine Circovirus Type 2a, <i>Mycoplasma hyopneumoniae</i> and <i>Lawsonia intracellularis</i> Vaccine in Weaned Pigs |
| title_full_unstemmed | Efficacy and Safety of a Tri-Valent Ready-to-Use Porcine Circovirus Type 2a, <i>Mycoplasma hyopneumoniae</i> and <i>Lawsonia intracellularis</i> Vaccine in Weaned Pigs |
| title_short | Efficacy and Safety of a Tri-Valent Ready-to-Use Porcine Circovirus Type 2a, <i>Mycoplasma hyopneumoniae</i> and <i>Lawsonia intracellularis</i> Vaccine in Weaned Pigs |
| title_sort | efficacy and safety of a tri valent ready to use porcine circovirus type 2a i mycoplasma hyopneumoniae i and i lawsonia intracellularis i vaccine in weaned pigs |
| topic | <i>Mycoplasma hyopneumoniae</i> <i>Lawsonia intracellularis</i> porcine circovirus combination vaccine |
| url | https://www.mdpi.com/2076-393X/13/7/681 |
| work_keys_str_mv | AT michelleallen efficacyandsafetyofatrivalentreadytouseporcinecircovirustype2aimycoplasmahyopneumoniaeiandilawsoniaintracellularisivaccineinweanedpigs AT frankroerink efficacyandsafetyofatrivalentreadytouseporcinecircovirustype2aimycoplasmahyopneumoniaeiandilawsoniaintracellularisivaccineinweanedpigs AT abigailcrowley efficacyandsafetyofatrivalentreadytouseporcinecircovirustype2aimycoplasmahyopneumoniaeiandilawsoniaintracellularisivaccineinweanedpigs AT susanknetter efficacyandsafetyofatrivalentreadytouseporcinecircovirustype2aimycoplasmahyopneumoniaeiandilawsoniaintracellularisivaccineinweanedpigs AT chandramorgan efficacyandsafetyofatrivalentreadytouseporcinecircovirustype2aimycoplasmahyopneumoniaeiandilawsoniaintracellularisivaccineinweanedpigs AT huilingwei efficacyandsafetyofatrivalentreadytouseporcinecircovirustype2aimycoplasmahyopneumoniaeiandilawsoniaintracellularisivaccineinweanedpigs AT ruudsegers efficacyandsafetyofatrivalentreadytouseporcinecircovirustype2aimycoplasmahyopneumoniaeiandilawsoniaintracellularisivaccineinweanedpigs |